Robert C. Green
Robert C. Green, MD, MPH is Professor of Medicine (Genetics) at Harvard Medical School and a physician-scientist who directs the G2P Research Program at Brigham and Women’s Hospital and the Broad Institute. Dr. Green is internationally recognized for clinical research and policy efforts accelerating the implementation of genomic/precision medicine. Dr. Green led the first experimental trials disclosing common complex disease risk (REVEAL Study) and the first prospective studies of direct-to-consumer genetic testing services (PGen Study). He led the first NIH-funded randomized trials of sequencing in adults (MedSeq Project), newborns (BabySeq Project), and active duty U..S military personnel (MilSeq Project). He created the concept of aggregate penetrance of genomic variants in prospective population cohorts and is demonstrating the feasibility of genomic sequencing in healthy newborns, paving the way for humans to gain lifelong medical benefits from genomics. Dr. Green serves as a Co-Principal Investigator FHS/JHS Return of Results study.
The NIH-funded network will implement and scale population-based genomic screening for common, actionable conditions in 25,000 adults in primary care settings across the U.S. Researchers at Ariadne Labs, a joint center for health systems innovation at Brigham and Women’s Hospital and the Harvard T.H. Chan School of Public Health, and partner institutions have received a… Continue reading Ariadne Labs and Collaborators Receive NIH Funding to Launch Major National Study Advancing Population Genomic Screening in Primary Care
Ariadne Labs is pleased to announce the appointment of Jason Vassy, MD, MPH, MS, as Director of Precision Population Health, ushering in the next chapter of the program’s work to advance the responsible and equitable integration of genomic medicine into health care. Dr. Vassy is a clinician-investigator at the VA Boston Healthcare System and Brigham… Continue reading Ariadne Labs Announces Jason Vassy as Director of Precision Population Health Program
Announcing the launch of BEACONS (Building Evidence and Collaboration for GenOmics in Nationwide Newborn Screening), the nation’s first multi-state genomic newborn screening initiative.
MGB coverage on the International Consortium of Newborn Sequencing (ICoNS) publishing of their findings and tool in Genetics in Medicine. They identified key factors influencing gene inclusion in newborn genomic screening programs and the team developed a machine learning model incorporating 13 predictors, achieving high accuracy in predicting gene selection across programs.
Dr. Robert Green pens a commentary in the Chicago Tribune on genetic testing and how some celebrities have raised awareness by sharing their genetic risks publicly.
The International Consortium of Newborn Sequencing (ICoNS) published their findings and tool in Genetics in Medicine. They identified key factors influencing gene inclusion in newborn genomic screening programs and the team developed a machine learning model incorporating 13 predictors, achieving high accuracy in predicting gene selection across programs.
Incorporating genetic sequencing into cancer screenings could facilitate early cancer detection.
